Current Report Filing (8-k)
December 20 2018 - 7:17AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 20, 2018
MIRAGEN THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
001-36483
|
|
47-1187261
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
6200 Lookout Rd.
Boulder, CO
|
|
80301
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code: (720)
643-5200
(Former name
or former address, if changed since last report)
Check the appropriate box below
if the Form
8-K
filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule
14a-12
under the Exchange Act (17
CFR
240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to Rule
14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to Rule
13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this
chapter) or Rule
12b-2
of the Securities Exchange Act of 1934 (§
240.12b-2
of this chapter).
Emerging growth company ☒
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act. ☐
Section 8 Other Events
On December 20, 2018, Miragen Therapeutics, Inc., a Delaware corporation (the Company), issued a press release titled Miragen
Therapeutics to Present New Cobomarsen Clinical Trial Data for Adult
T-Cell
Leukemia/Lymphoma and Cutaneous
T-Cell
Lymphoma at the 11
th
Annual
T-Cell
Lymphoma Forum in which the Company provided an update regarding its global Phase 2 SOLAR trial for cobomarsen, the Companys
clinical product candidate for the treatment of certain cancers, in patients diagnosed with cutaneous
T-cell
lymphoma. As of December 20, 2018, the Phase 2 SOLAR trial is in the startup phase with the
first 4 clinical sites in the United States open for enrollment with initial dosing expected by early 2019.
A copy of the press release is filed as
Exhibit 99.1 to this Current Report on
Form 8-K and
is incorporated herein by reference.
Section 9 Financial Statements and Exhibits
Item 9.01
|
Financial Statements and Exhibits.
|
(d) Exhibits
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
Miragen Therapeutics, Inc.
|
|
|
|
|
Dated: December 20, 2018
|
|
|
|
By:
|
|
/s/ Jason A. Leverone
|
|
|
|
|
|
|
Jason A. Leverone
|
|
|
|
|
|
|
Chief Financial Officer
|
Miragen Therapeutics (NASDAQ:MGEN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Miragen Therapeutics (NASDAQ:MGEN)
Historical Stock Chart
From Sep 2023 to Sep 2024